The epidermal growth factor receptor ligand amphiregulin participates in the development of mouse liver fibrosis
Open Access
- 9 June 2008
- journal article
- research article
- Published by Ovid Technologies (Wolters Kluwer Health) in Hepatology
- Vol. 48 (4), 1251-1261
- https://doi.org/10.1002/hep.22437
Abstract
The hepatic wound-healing response to chronic noxious stimuli may lead to liver fibrosis, a condition characterized by excessive deposition of extracellular matrix. Fibrogenic cells, including hepatic stellate cells and myofibroblasts, are activated in response to a variety of cytokines, growth factors, and inflammatory mediators. The involvement of members of the epidermal growth factor family in this process has been suggested. Amphiregulin (AR) is an epidermal growth factor receptor (EGFR) ligand specifically induced upon liver injury. Here, we have addressed the in vivo role of AR in experimental liver fibrosis. To this end, liver fibrosis was induced in AR+/+ and AR−/− mice by chronic CCl4 administration. Histological and molecular markers of hepatic fibrogenesis were measured. Additionally, the response of cultured human and mouse liver fibrogenic cells to AR was evaluated. We observed that AR was expressed in isolated Kupffer cells and liver fibrogenic cells in response to inflamatory stimuli and platelet-derived growth factor, respectively. We demonstrate that the expression of α-smooth muscle actin and collagen deposition were markedly reduced in AR−/− mice compared to AR+/+ animals. AR−/− mice also showed reduced expression of tissue inhibitor of metalloproteinases-1 and connective tissue growth factor, two genes that responded to AR treatment in cultured fibrogenic cells. AR also stimulated cell proliferation and exerted a potent antiapoptotic effect on isolated fibrogenic cells. Conclusion: These results indicate that among the different EGFR ligands, AR plays a specific role in liver fibrosis. AR may contribute to the expression of fibrogenic mediators, as well as to the growth and survival of fibrogenic cells. Additionally, our data lend further support to the role of the EGFR system in hepatic fibrogenesis. (HEPATOLOGY 2008.)This publication has 43 references indexed in Scilit:
- Models of liver fibrosis: exploring the dynamic nature of inflammation and repair in a solid organJCI Insight, 2007
- Hepatic fibrosis and cirrhosis: The (myo)fibroblastic cell subpopulations involvedThe International Journal of Biochemistry & Cell Biology, 2006
- Modern pathogenetic concepts of liver fibrosis suggest stellate cells and TGF‐β as major players and therapeutic targetsJournal of Cellular and Molecular Medicine, 2006
- HEPATIC FIBROSIS: Molecular Mechanisms and Drug TargetsAnnual Review of Pharmacology and Toxicology, 2005
- Liver fibrosisJCI Insight, 2005
- Liver extracellular matrix in health and diseaseThe Journal of Pathology, 2003
- Molecular basis of hepatic fibrosisExpert Reviews in Molecular Medicine, 2003
- Hepatic stellate cell/myofibroblast subpopulations in fibrotic human and rat liversJournal of Hepatology, 2002
- Localization of liver myofibroblasts and hepatic stellate cells in normal and diseased rat livers: distinct roles of (myo-)fibroblast subpopulations in hepatic tissue repairHistochemistry and Cell Biology, 1999
- Effects of platelet-derived growth factor and other polypeptide mitogens on DNA synthesis and growth of cultured rat liver fat-storing cells.JCI Insight, 1989